- ISIN
- US09058V1035
- CUSIP
- 09058V103
- Sector
- Healthcare
- Industry
- Biotechnology
- IPO Date
- Mar 3, 1994
Highlights
- Market Cap
- $2.21B
- Enterprise Value
- $2.06B
- EPS (TTM)
- -$2.03
- Total Revenue (TTM)
- $885.72M
- Gross Profit (TTM)
- $167.34M
- EBITDA (TTM)
- -$374.88M
- Year Range
- $6.00 - $10.32
- Target Price
- $16.86
- ROA (TTM)
- -98.48%
- ROE (TTM)
- 82.69%
Share Price Chart
Loading charts...
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
BCRX Performance Chart
BioCryst Pharmaceuticals, Inc. (BCRX) is up 17.2% since the beginning of the year. At $9 per share, BCRX is trading 11.4% below its 52-week high of $10. Investors who bought $1,000 worth of BCRX shares 5 years ago would now be looking at an investment worth $538.
Loading charts...
Returns By Period
BioCryst Pharmaceuticals, Inc. (BCRX) has returned 17.18% so far this year and -9.50% over the past 12 months. Over the last ten years, BCRX has returned 12.40% per year, falling short of the S&P 500 Index benchmark, which averaged 13.88% annually.
BioCryst Pharmaceuticals, Inc.
- 1D
- 1.67%
- 1M
- 10.25%
- YTD
- 17.18%
- 6M
- 20.11%
- 1Y
- -9.50%
- 3Y*
- 9.25%
- 5Y*
- -11.66%
- 10Y*
- 12.40%
Benchmark (S&P 500 Index)
- 1D
- -0.37%
- 1M
- -0.01%
- YTD
- 9.16%
- 6M
- 8.64%
- 1Y
- 25.22%
- 3Y*
- 19.78%
- 5Y*
- 11.99%
- 10Y*
- 13.88%
BCRX Monthly Returns History
Based on dividend-adjusted daily data since Mar 4, 1994, BCRX's average daily return is +0.14%, while the average monthly return is +2.76%. At this rate, an investment would double in approximately 2.1 years.
Historically, 51% of months were positive and 49% were negative. The best month was Jul 2013 with a return of +183.9%, while the worst month was Feb 2016 at -71.5%. The longest winning streak lasted 10 consecutive months, and the longest losing streak was 6 months.
On a daily basis, BCRX closed higher 45% of trading days. The best single day was Apr 27, 2009 with a return of +75.6%, while the worst single day was Feb 8, 2016 at -71.0%.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | -15.64% | 32.98% | 8.80% | -3.78% | -2.73% | 2.58% | 17.18% | ||||||
| 2025 | 5.05% | 8.99% | -12.89% | 18.00% | 21.47% | -16.65% | -9.15% | 2.09% | -8.66% | -3.56% | -1.91% | 8.64% | 3.72% |
| 2024 | -11.52% | 6.23% | -9.77% | -18.70% | 56.42% | -4.33% | 17.80% | 19.37% | -12.54% | 5.39% | -6.37% | 0.27% | 25.54% |
| 2023 | -8.10% | -16.11% | -5.76% | -8.75% | 8.67% | -14.87% | 4.97% | -3.79% | -0.42% | -22.46% | 7.10% | 1.87% | -47.82% |
| 2022 | 11.55% | 7.51% | -2.11% | -42.87% | 0.22% | 13.64% | 4.16% | 26.13% | -9.35% | 5.95% | 0.07% | -14.07% | -17.11% |
| 2021 | 14.36% | 26.53% | -5.66% | 14.41% | 35.54% | 0.25% | 1.96% | -1.24% | -9.74% | 3.90% | -19.22% | 14.84% | 85.91% |
Benchmark Metrics
BioCryst Pharmaceuticals, Inc. has an annualized alpha of 27.43%, beta of 1.11, and R2 of 0.06 versus S&P 500 Index. Calculated based on daily prices since March 04, 1994.
- This stock participated in 143.09% of S&P 500 Index downside but only 114.21% of its upside - more exposed to losses than it benefited from rallies.
- R2 of 0.06 means this stock moves largely independently of S&P 500 Index - capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.
- Alpha
- 27.43%
- Beta
- 1.11
- R²
- 0.06
- Upside Capture
- 114.21%
- Downside Capture
- 143.09%
Return for Risk
Risk / Return Rank
BCRX ranks 33 for risk / return — below 33% of stocks on our site. The returns aren't fully compensating for the risk involved. This isn't necessarily a dealbreaker, but factor it into your decision — especially if you're risk-averse.
Return / Risk — by metrics
The table below present risk-adjusted performance metrics for BioCryst Pharmaceuticals, Inc. (BCRX) and compare them to S&P 500 Index.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| BCRX | Benchmark | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | -2.24 | ||
| Sortino ratioReturn per unit of downside risk | -2.76 | ||
| Omega ratioGain probability vs. loss probability | 1.00 | 1.37 | -0.37 |
| Calmar ratioReturn relative to maximum drawdown | -0.26 | 2.78 | -3.04 |
| Martin ratioReturn relative to average drawdown | -0.46 | 12.44 | -12.90 |
Dividends
Dividend History
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Loading charts...
Worst Drawdowns
The table below displays the maximum drawdowns of the BioCryst Pharmaceuticals, Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the BioCryst Pharmaceuticals, Inc. was 97.74%, occurring on Jul 3, 2002. The portfolio has not yet recovered.
The current BioCryst Pharmaceuticals, Inc. drawdown is 72.41%.
Related event | Drawdown | Fall | Recovery | Underwater |
|---|---|---|---|---|
Dot-com crash2000–2002 | -97.74%Jul 2002 | 1y 10mo | — | 25y 10moAug 2000 - now |
1998 bear market1998 | -75.98%Oct 1998 | 2y 3mo | 10mo 8d | 3y 1moJun 1996 - Aug 1999 |
Dot-com crash2000–2002 | -50.76%Apr 2000 | 1mo 9d | 3mo 17d | 4mo 26dMar 2000 - Aug 2000 |
1994 bear market1994 | -47.17%Apr 1994 | 1mo 10d | 10mo 27d | 1y 2dMar 1994 - Mar 1995 |
1995 bear market1995 | -40.80%Jun 1995 | 1d | 10mo 4d | 10mo 5dJun 1995 - Apr 1996 |
Drawdown Indicators
| BCRX | Benchmark | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -97.74% | -56.78% | -40.96% |
Max Drawdown (1Y)Largest decline over 1 year | -37.16% | -9.10% | -28.06% |
Max Drawdown (3Y)Largest decline over 3 years | -47.85% | -18.90% | -28.95% |
Max Drawdown (5Y)Largest decline over 5 years | -79.10% | -25.43% | -53.67% |
Max Drawdown (10Y)Largest decline over 10 years | -83.69% | -33.92% | -49.77% |
Current DrawdownCurrent decline from peak | -72.41% | -1.80% | -70.61% |
Average DrawdownAverage peak-to-trough decline | -69.64% | -10.71% | -58.93% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 21.92% | 2.03% | +19.89% |
Volatility
Volatility Chart
The chart below shows the rolling one-month volatility.
Loading charts...
Financials
Financial Performance
The chart below illustrates the trends in the financial health of BioCryst Pharmaceuticals, Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.
Valuation
The Valuation section provides an overview of how BioCryst Pharmaceuticals, Inc. is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.
PS Ratio
This chart shows the Price-to-Sales (P/S) ratio for BCRX relative to other companies in the Biotechnology industry. Currently, BCRX has a P/S ratio of 2.3. This P/S ratio is low compared to the industry average. It may indicate that the stock is undervalued relative to its revenue, or that the market expects slower growth or lower margins.
Income Statement
| TTM | |
|---|---|
Revenue | — |
Total Revenue | — |
Cost Of Revenue | — |
Gross Profit | — |
Operating Expenses | — |
Selling, General & Admin Expenses | — |
R&D Expenses | — |
Depreciation And Amortization | — |
Total Operating Expenses | — |
Income | — |
Income Before Tax | — |
Operating Income | — |
EBITDA | — |
EBIT | — |
Earnings From Continuing Operations | — |
Net Income | — |
Income Tax Expense | — |
Other Non-Operating Income (Expenses) | — |
Extraordinary Items | — |
Discontinued Operations | — |
Effect Of Accounting Charges | — |
Non Recurring | — |
Minority Interest | — |
Other Items | — |
Interest Income | — |
Interest Expense | — |
Net Interest Income | — |
Build a portfolio with BCRX
Add BioCryst Pharmaceuticals, Inc. to a portfolio and analyze allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Analyzer with BCRX